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Abstract
Background: According to Rome criteria, chronic constipation (CC) includes functional constipation (FC)
and irritable bowel syndrome with constipation (IBS-C). Some patients do not meet these criteria (No Rome
Constipation, NRC). The aim of the study was is to evaluate the various clinical presentation and management of
FC, IBS-C and NRC in Italy.
Methods: During a 2-month period, 52 Italian gastroenterologists recorded clinical data of FC, IBS-C and NRC
patients, using Bristol scale, PAC-SYM and PAC-QoL questionnaires. In addition, gastroenterologists were also asked
to record whether the patients were clinically assessed for CC for the first time or were in follow up. Diagnostic
tests and prescribed therapies were also recorded.
Results: Eight hundred seventy-eight consecutive CC patients (706 F) were enrolled (FC 62.5%, IBS-C 31.3%, NRC 6.
2%). PAC-SYM and PAC-QoL scores were higher in IBS-C than in FC and NRC. 49.5% were at their first
gastroenterological evaluation for CC. In 48.5% CC duration was longer than 10 years. A specialist consultation was
requested in 31.6%, more frequently in IBS-C than in NRC. Digital rectal examination was performed in only 56.4%.
Diagnostic tests were prescribed to 80.0%. Faecal calprotectin, thyroid tests, celiac serology, breath tests were more
frequently suggested in IBS-C and anorectal manometry in FC. More than 90% had at least one treatment
suggested on chronic constipation, most frequently dietary changes, macrogol and fibers. Antispasmodics and
psychotherapy were more frequently prescribed in IBS-C, prucalopride and pelvic floor rehabilitation in FC.
Conclusions: Patients with IBS-C reported more severe symptoms and worse quality of life than FC and NRC.
Digital rectal examination was often not performed but at least one diagnostic test was prescribed to most
patients. Colonoscopy and blood tests were the “first line” diagnostic tools. Macrogol was the most prescribed
laxative, and prucalopride and pelvic floor rehabilitation represented a “second line” approach. Diagnostic tests and
prescribed therapies increased by increasing CC severity.
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Background
Chronic constipation (CC) is a common and ex-
tremely troublesome disorder that has a negative im-
pact on social and professional life, reduces the
quality of life (QoL) and represents a heavy economic
burden [1–5]. CC affects about 12–17% of the world
population, with a higher prevalence among females
and elderly people [6–9].
A considerable amount (16 to 40%) of CC patients in
different countries use laxatives, and their use is related
to increasing age, symptom frequency and duration of
constipation; in the USA more than $800 million are
spent on laxatives each year [10, 11].
The most widely used criteria to assess CC are the
Rome Criteria [12] (Table 1) which separate constipation
in functional constipation (FC) and irritable bowel syn-
drome with constipation (IBS-C). The presence of ab-
dominal pain relieved by defecation characterizes IBS-C.
Moreover, some patients consider themselves consti-
pated even when not showing signs or symptoms
consistent with Rome criteria (here defined as “No-
Rome Constipation”, NRC) [13].
At present it is unclear whether gastroenterologists
use the same diagnostic and therapeutic approach in
these different groups of patients.
Objective of the study
Primary endpoints
 To describe the diagnostic tools used and the
treatments suggested by Italian gastroenterologists
for CC patients.
Secondary endpoints
 To assess, among CC patients, the distribution of
FC, IBS-C and NRC and the severity of symptoms
and QoL.
 To evaluate whether the diagnosis of FC, IBS-C and
NRC could affect the use of the diagnostic tools and
the choice of the therapy.
 To evaluate other possible potential factors affecting
the use of the diagnostic tools and the therapeutic
choices in CC patients.
Methods
Study population and questionnaires
Fifty two gastroenterologists belonging to different
gastroenterological units in Italy on behalf of the Italian
Association of Hospital Gastroenterologists and Endos-
copists (AIGO), recorded clinical and demographic data
of all patients consecutively referred for CC in a two
month period (September-October 2013).
Bristol scale [14] was used to assess the stool consistency
in the previous three months, while symptoms were classi-
fied according to Rome III criteria in order to verify
whether the patients could be diagnosed as FC, IBS-C, or
NRC. In addition, gastroenterologists were also asked to
record whether the patients were clinically assessed for CC
for the first time or were in follow up. Diagnostic tests, rec-
ommended specialist consultations and prescribed therap-
ies were also recorded.
Furthermore, patients were required to fill the Patient
Assessment of Constipation-Symptoms (PAC-SYM) and
the Patient Assessment of Constipation-Quality of Life
(PAC-QoL) questionnaires.
PAC-SYM is a 12-item self-reported questionnaire devel-
oped to assess the frequency and severity of CC symptoms.
It is divided into three symptom subscales: abdominal
(items 1–4), rectal (items 5–7), and stool (items 8–12) [15].
PAC-QoL is a 28 item self-reported questionnaire used
to measure the patient’s QoL. It is divided into four sub-
scales: physical discomfort (items 1–4), psychosocial dis-
comfort (items 5–12), worries and concerns (items 12–23),
and satisfaction (items 24–28) [16].
Table 1 Rome III criteria for functional constipation and irritable
bowel syndrome
Functional Constipation
Diagnostic criteriaa
1. Must include two or more of the following:
α. Straining during at least 25% of defecations
β. Lumpy or hard stools in at least 25% of defecations
γ. Sensation of incomplete evacuation for at least 25% of defecations
δ. Sensation of anorectal obstruction/blockage for at least 25% of
defecations
ε. Manual manoeuvres to facilitate at least 25% of defecations (e.g.
digital evacuation, support of the pelvic floor)
η. Fewer than three defecations per week
2. Loose stools are rarely present without the use of laxatives
3. Insufficient criteria for irritable bowel syndrome
aCriteria fulfilled for the last 3 months with symptoms onset at least
6 months prior to diagnosis
Irritable Bowel Syndrome with Constipation
Diagnostic criteriaa
Recurrent abdominal pain or discomfort b at least 3 days/month in
the last 3 months associated with two or more of the following:
-Improvement with defecation
-Onset associated with a change in frequency of stool
-Onset associated with a change in form (appearance) of stool (hard
or lumpy stools ≥25% and loose or watery stools <25% of bowel
movements)
aCriteria fulfilled for the last 3 months with symptoms onset at least 6 months
prior to diagnosis
b “Discomfort” means an uncomfortable sensation not described as pain
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For both questionnaires, items are scored on a five-
point Likert scale (0–4), with 4 indicating the worst
symptom severity.
Inclusion criteria
-Patients aged over 18 years evaluated for CC.
Exclusion criteria
-Presence of known or suspected severe organic disease
potentially causing constipation and/or psychiatric
disease potentially interfering with questionnaires
compilation.
-Patients assuming potentially constipating drugs
or the onset of constipation after starting any kind
of drug.
Statistical analysis
Data were analyzed by means of the SAS® System for
Windows, version 9.2.
A prevalence approach was adopted and no imput-
ation was performed for any missing data.
The association between categorical variables was
analyzed using Chi-Square test or Fisher’s exact test
(for cell frequencies < 5). In order to correct for mul-
tiple comparisons, pairwise tests were adjusted using
the Bonferroni method.
The association between a continuous and a categor-
ical variable (with two categories) was analyzed by the
Wilcoxon-Mann–Whitney test. Finally, the association
between a continuous and a categorical variable was an-
alyzed by the Kruskal-Wallis test (or by the ANOVA in
case of normal distribution). In case of pairwise compar-
isons, the Dunn’s test was performed. The correlation
between two continuous variables was summarized by
the Pearson’s correlation coefficient in case of normal
data distribution, or by the Spearman’s correlation coef-
ficient otherwise.
All statistical tests were performed with a two-sided
significance level α = 0.05, therefore p-values lower than
0.05 were considered statistically significant.
The PAC-SYM and PAC-QoL total and domain scores
were calculated as detailed in Additional file 1, respectively.
PAC-SYM total score and PAC-QoL total score were
also analyzed through multivariate regression models,
adjusting for the following independent variables: age,
sex, diagnosis, duration of CC.
Results
Data from 878 CC patients (33.9% in Northern Italy,
32.4% in Center Italy and 33.7% in Southern Italy),
706 women (80.4%) and 172 men (19.6%), mean age:
51.0 ± 16.8 years (F 49.6 ± 16.6 years; M 56.9 ±
16.5 years) were obtained. Their body mass index
(BMI) was 23.7 ± 4.0 kg/m2. Four hundred thirty-five
out of 878 patients (49.5%) were at their first gastro-
enterological evaluation for CC. According to Rome
III criteria the patients were classified as FC: 549
(62.5%); IBS-C: 275 (31.3%); NRC: 54 (6.2%).
IBS-C patients were younger (46.9 ± 16.2 years) than
FC (52.8 ± 16.6) and NRC (53.1 ± 18.6) (p < 0.0001).
The gender distribution was significantly different
between the three groups (IBS-C: women 234/275
(85.1%); FC: women 433/549 (78.9%); NRC: women
39/54 (72.2%) (p < 0.05) .
The duration of CC was “>1–4 years” in 23.1% (IBS-C:
33.0%; FC: 59.1%; NRC: 7.9%), “≥5years” in 21.1% (IBS-
C: 27.0%; FC: 65.4%; NRC: 7.6%) and “>10 years” in
48.5% of the patients (IBS-C: 32.2%; FC: 63.9%; NRC:
4.0%). No significant difference was observed between
groups but only a trend toward a shorter duration in
NRC could be detected.
Bristol 1–2 was reported in 628/878 (71.5%) patients
(IBS-C: 208/275, 75.6%; FC:394/549, 71.8%; NRC: 26/54,
48.2%) (IBS-C vs FC: ns; IBS-C vs. NRC: p < 0.001; FC vs
NRC: p < 0.005).
As shown in Table 2, 73.2% of patients reported at
least one comorbidity in the previous year: depres-
sion and anxiety were more frequent in IBS-C com-
pared to FC (p < 0.01) and NRC (p < 0.005), as well
as dyspepsia (p < 0.05 vs. FC and NRC). Gastroesophageal
reflux disease was more frequent in IBS-C compared to
NRC (p < 0.01) and in FC compared to NRC (p < 0.05).
Hypertension was found more frequently in FC than in
IBS-C (p < 0.05).
The results of PAC-SYM are shown in Table 3:
IBS-C mean total score was higher than FC and
NRC (p < 0.0001) ones. The multivariate regression
model suggested that the total score of PAC-SYM
(mean: 1.6 ± 0.7) was directly related to the duration of
constipation (p < 0.01), and to younger age (p < 0.0001).
Abdominal symptoms subscale was significantly higher in
IBS-C than in FC (p < 0.05) and in NRC (p < 0.0001). In
particular, a positive association was detected between
each of the first four items (discomfort, pain, bloating
and stomach cramps) which constitutes the abdominal
subscale and IBS-C (p < 0.0001). Fecal symptoms sub-
scale was significantly higher in FC and IBS-C than
NRC (p < 0.01). Furthermore, there was a positive cor-
relation of the total PAC-SYM score with the number
of diagnostic tests (p < 0.0005) and of suggested ther-
apies (p < 0.05).
In Table 4 the results of PAC-QoL are shown:
IBS–C mean total score was higher than FC and
NRC (p < 0.001); all the subscales, excluding the sat-
isfaction subscale, were significantly higher in IBS-C
and in FC than in NRC. Moreover, the multivariate
regression model for the total score of PAC-QoL
(mean: 1.8 ± 0.7) shows that this was neither related to
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gender, nor to age or duration of constipation. There was
a statistically significant positive correlation with the num-
ber of diagnostic tests (p < 0.05), the number of suggested
therapies (p < 0.0001) and the number of specialist consul-
tations (p < 0.005).
Digital rectal examination (DRE) was performed in
495/878 (56.4%), independently from the patients be-
ing at their first evaluation (54.7%) or at a follow up
visit (56.6%). No relationship with gender was found
(104 M: 61.3%; F 391: 55.2%). Patients in whom a
DRE was performed were older (52.6 ± 16.6 years vs.
49.4 ± 16.7; p < 0.01), and DRE was more often per-
formed by gastroenterologists aged over 40 years than
by younger ones (60.1% vs. 44.6%; p < 0.0001).
At least a specialist consultation was requested in
277/878 (31.6%) patients, mostly psychiatric/psycho-
logical (11.5%), urological (8.1%) and gynecological
(12.3% of the women) (Table 5). In IBS-C psychiatric/
psychological and gynaecological consultations were
more frequently requested than in NRC (p < 0.05).
Diagnostic tests were requested in 702/878 (80.0%)
of the patients. Table 6 shows the different tests re-
quested in the whole sample and in the different
diagnosis subgroups (IBS-C, FC and NRC). Fecal cal-
protectin was more frequently prescribed in IBS-C
than in FC and NRC (p < 0.0001 and p < 0.05, re-
spectively). Thyroid function tests (p < 0.05), serology
for celiac disease (p < 0.005), lactose breath test (p <
0.01) and glucose breath test (p < 0.05) were more
frequently suggested in IBS-C than in FC, whereas
in FC anorectal manometry was more frequently
prescribed than in IBS-C (p < 0.05) and defecography
more frequently than in NRC (p < 0.05). Abdominal
ultrasonography was suggested in 22% of the pa-
tients without significant differences among groups.
Colonoscopy was suggested more in patients ≥50 years
than in those <50 years (52.3% vs. 22.5%; p < 0.0001),
more in males than in females (51.2% vs. 35.6%; p < 0.001)
and more often at first evaluation than at follow-up
(43.2% vs. 32.8%; p < 0.005). Also, routine blood tests
Table 2 Prevalence of comorbidities
IBS-C: 275 FC: 549 NRC: 54 p-value1
Dyspepsia 128 (46.5%) 200 (36.4%) 14 (25.9%)# <0.005
Depression/anxiety 111 (40.4%) 164 (29.9%)* 9 (16.7%)** <0.0005
GERD 98 (35.6%) 167 (30.4%) 8 (14.8%)## ### <0.01
Sleep disturbances 87 (31.6%) 141 (25.7%) 13 (24.1%) ns
Hypertension 45 (16.4%) 135 (24.6%)§ 11 (20.4%) <0.05
Urinary disturbances 52 (18.9%) 115 (20.9%) 8 (14.8%) ns
Thyroid disease 26 (9.4%) 65 (11.8%) 6 (11.1%) ns
Vaginitis 29 (10.5%) 46 (8.4%) 4 (7.4%) ns
Dyspareunia 30 (10.9%) 38 (6.9%) 4 (7.4%) ns
Diabetes 7 (2.5%) 29 (5.3%) 3 (5.6%) ns
Fibromyalgia 16 (5.8%) 18 (3.3%) - ns
Other 36 (13.1) 56 (10.2%) 7 (13%) ns
IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria, GERD gastroesophageal
reflux disease
1p values are referred to the differences between IBS-C, FC and NRC groups, in particular
*p < 0.01 vs IBS-C; **p < 0.005 vs IBS-C; #p < 0.05 vs IBS-C and FC; ##p < 0.01 vs IBS-C
###p < 0.05 vs FC; §p < 0.05 vs IBS-C; ns: not statistically significant
Table 3 PAC-SYM total score and abdominal, rectal and faecal symptoms subscales: mean values ± SD in all patients and in IBS-C,
FC and NRC subgroups
ALL PATIENTS IBS-C FC NRC p-value1
Total score 1.6 ± 0.70 1.75 ± 0.70* 1.56 ± 0.68 1.31 ± 0.70 p < 0.0001
Abdominal symptoms 1.53 ± 0.88 1.91 ± 0.74#§ 1.37 ± 0.88 1.19 ± 0.86 p < 0.0001
Rectal symptoms 0.88 ± 0.86 0.98 ± 0.92 0.85 ± 0.83 0.70 ± 0.78 ns
Faecal symptoms 2.09 ± 0.91 2.09 ± 0.88 2.13 ± 0.92 1.74 ± 0.88^ p < 0.01
IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria
1p values are referred to the differences between IBS-C, FC and NRC groups, in particular * p < 0.0001 vs FC and NRC; # p < 0.0001 vs NRC; § p < 0.05 vs FC;
^ p < 0.01 vs IBS-C and FC; ns: not statistically significant
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(61.2% vs. 46.6%; p < 0.0001), thyroid function tests
(52.0% vs. 40.2%,; p < 0.001), carcinoembryonic antigen
(11.3% vs. 6.4%; p < 0.05), serology for celiac disease
(19.1% vs. 13.2%; p < 0.05); and stool culture and test
for ova and parasites (9.7% vs. 4.2%; p < 0.005) were
requested more often at first evaluation than at
follow-up. On the contrary defecography (2.5% vs.
5.6%; p < 0.05) was suggested less frequently at first
visit than at follow-up. Serology for celiac disease
was suggested more frequently in patients <50 years
old than in patients ≥50 years old (22.0% vs. 11.3%;
p < 0.0001).
Table 7 shows the suggested therapies, overall and by
diagnosis. In 863/878 patients (98.3%) at least one treat-
ment was given. Lifestyle and dietary changes were the
most frequent suggestions, whereas macrogol and fiber
supplements were largely the most frequently prescribed
substances.
Macrogol was suggested more frequently in FC (71.6%)
and IBS-C (70.9%) than in NRC (42.6%; p < 0.0001). A
fiber supplements prescription was slightly more
frequent in IBS-C, but no significant difference was
detected among IBS-C, FC and NRC. In IBS-C anti-
spasmodics were used more frequently compared to
FC and NRC (27.6% vs. 11.7% vs. 11.1%; p < 0.0001
and p > 0.05, respectively). Antibloating agents (29.1%
vs. 18.6%; p < 0.005) and psychotherapy (6.9% vs.
2.7%; p < 0.05) were most frequently prescribed in
IBS-C than in FC, whereas pelvic floor rehabilitation
was more frequently suggested in FC than in IBS-C
(22.2% vs. 14.6%; p < 0.05).
Lactulose/lactitole (8.6% vs. 4.3%; p < 0.05), suppositor-
ies/micro-enemas (26.4% vs. 18.2%; p < 0.005), intestinal
antibiotics (9.0% vs. 3.0%; p < 0.0005), antidepressants
(10.0% vs. 3.0%; p < 0.0001), anxiolytics (15.9% vs. 8.1;
p < 0.001) and pelvic floor rehabilitation (22.0% vs.
15.7%; p < 0.05) were more frequently suggested in pa-
tients ≥50 years than in patients <50 years, whereas
antispasmodics were more frequently prescribed in
patients <50 years than in patients ≥50 years (20.0%
vs. 13.8%; p < 0.05).
Enemas and micro-enemas/suppositories were mainly
prescribed not on a daily basis but usually every other
day or on demand (24.2% and 19.7%, respectively).
Lifestyle changes (87.5% vs. 80.9%; p < 0.05) and diet-
ary suggestions (91.1% vs. 83.9%; p < 0.05) were more
frequently prescribed in males than in females, but
anorectal surgery only in females (2.8%).
Table 4 PAC-QoL total score and subscales (mean values ± SD) in all patients and in IBS-C, FC and NRC subgroups
ALL PATIENTS IBS-C FC NRC p-value1
Total score 1.77 ± 0.69 1.97 ± 0.70 1.71 ± 0.68 1.44 ± 0.62* p < 0.001
Physical discomfort 1.85 ± 0.88 2.13 ± 0.82 1.75 ± 0.88 1.42 ± 0.82* p < 0.001
Psychosocial discomfort 1.12 ± 0.83 1.38 ± 0.83 1.02 ± 0.80 0.77 ± 0.73* p < 0.001
Worries and concerns 1.72 ± 0.92 1.92 ± 0.93 1.65 ± 0.90 1.36 ± 0.80* p < 0.001
Satisfaction 2.90 ± 0.71 2.89 ± 0.72 2.92 ± 0.69 2.74 ± 0.81 ns
IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria
1p values are referred to the differences between IBS-C, FC and NRC groups, in particular
* p < 0.001 vs IBS-C and FC; ns: not statistically significant
Table 5 Specialist consultations requested by the gastroenterologists after their visit
CONSULTATION 878 pts. (%) IBS-C (%) FC (%) NRC (%) p-value1
Psychiatrist/psychologist 101 (11.5) 16.0 10.0 3.7* <0.01
Gynaecologista 87(12.3) 15.4 11.6 2.6* <0.05
Urologist 71 (8.1) 8.0 8.4 5.6 ns
Surgeon 66 (7.5) 6.6 7.8 9.3 ns
Physiatrist/Physiotherapist 49 (5.6) 6.2 5.8 - ns
Dietician 46 (5.2) 4.0 5.8 5.6 ns
Rheumatologist 15 (1.7) 2.6 1.3 1.9 ns
Neurological 15 (1.7) 1.8 1.6 1.9 ns
Other 17 (1.9) 2.6 1.8 - ns
IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria
acalculated on the women sample visited
1p values are referred to the differences between IBS-C, FC and NRC groups, in particular; *vs IBS-C and FC; ns: not statistically significant
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Probiotics were most frequently prescribed at first
visit than at follow-up (40.9% vs. 31.5%; p < 0.01),
whereas prucalopride and pelvic floor rehabilitation
were more often prescribed during a follow-up visit
than at first evaluation (20.1% vs. 10.6%, p < 0.0001;
23.8% vs. 15.4%, p < 0.005, respectively).
A mix of suggestions and drugs was used in many
patients: in 59.5% lifestyle suggestions, changes in
diet and macrogol; in 50.8% lifestyle suggestions,
changes in diet and fiber supplementation; in 37.2%
changes in diet, fiber supplementation and macrogol;
in 37.1% lifestyle suggestions, fiber supplementation
and macrogol; in 33.3% lifestyle suggestions, changes
in diet and probiotics.
Discussion
The present study conveys an important educational
message for general practitioners, who see the major-
ity of constipated patients, and for other specialists
who could visit patients for possible comorbidities:
when collecting the patient’s history, the presence of
constipation should be accurately searched and
treated (if possible). Waiting so many years before
sending constipated patients to a gastroenterologist
simply means worsening a patient’s symptoms and
his/her QoL [4] and increasing the risk to develop
important anatomical alterations such as perineal
descent, rectocele, rectal intussusceptions, prolapse,
enterocele or sigmoidocele, or increase his/her cardio-
vascular mortality [17].
Rome criteria seemed accurate to identify constipated
patients, since only 6.2% showed NRC.
NRC patients were usually older and often male
than IBS-C, and reported fewer and less severe symp-
toms, softer stools and a better QoL than FC and
IBS-C. On the other hand, IBS-C patients were youn-
ger and more often female, reported more severe
symptoms, harder stools and a worse QoL than NRC
Table 6 Diagnostic test requested by the gastroenterologist after their visit
DIAGNOSTIC TEST 878 pts.(%) IBS-C (%) FC (%) NRC (%) p-value1
Routine blood tests 472 (53.8) 58.9 51.6 50.0 ns
Thyroid function tests 400 (45.6) 52.4 # 43.2 35.2 <0.05
Colonoscopy 339 (38.6) 34.6 40.6 38.9 ns
Anorectal manometry 306 (34.9) 29.8 # 38.6 22.2 <0.01
Colonic transit time 228 (26.0) 30.6 24.6 16.7 ns
Abdominal ultrasonography 193 (22.0) 22.6 22.2 16.7 ns
RX Defecography 167 (19.0) 16.4 21.5 ° 7.4 <0.05
Faecal blood test 153 (17.4) 14.9 18.8 16.7 ns
Coeliac serology 142 (16.2) 22.6^ 13.1 14.8 <0.005
Carcinoembryonic
antigen assay
78 (8.9) 6.6 9.8 11.1 ns
Faecal calprotectin 64 (7.3) 15.3 * ** 3.8 1.9 <0.0001
Stool culture, test for ova
and parasites
62 (7.1) 6.6 8.0 - ns
Lactose Breath Test 35 (4.0) 7.3 § 2.7 - <0.005
MR Defecography 33 (3.8) 2.6 4.2 5.6 ns
Trans-anal ultrasound 30 (3.4) 4.7 2.9 1.9 ns
Rectosigmoidoscopy 22 (2.5) 2.9 2.6 - ns
Virtual colonoscopy 19 (2.2) 1.8 2.4 1.9 ns
Barium Enema 14 (1.6) 1.1 1.8 1.9 ns
Glucose Breath test 12 (1.4) 2.9 # 0.7 - <0.05
Colonic manometry 12 (1.4) 1.8 1.1 1.9 ns
Anal Sphincter
Electromyography
5 (0.6%) 0.7 0.6 - ns
Other 34 (3.9) 4.7 3.6 1.9 ns
IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria
1p values are referred to the differences between IBS-C, FC and NRC groups, in particular
# p < 0.05 vs FC; * p < 0.0001 vs FC; ** p < 0.05 vs NRC; ^ p < 0.005 vs FC; § p < 0.01 vs FC; ° p < 0.05 vs NRC; ns: not statistically significant
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and FC. Our results show that Rome III criteria iden-
tify patients with more severe constipation.
Recently the new Rome IV criteria have been pub-
lished [18]. No substantial differences have been in-
troduced regarding definition and classification of
functional constipation: simply they state that “ab-
dominal pain and/or bloating may be present but are
not predominant symptoms (ie, the patient does not
meet criteria for IBS)”. Regarding IBS the term dis-
comfort was eliminated and the frequency of abdom-
inal pain became at least 1 day per week instead of
3 days per month. However we think that these
changes would not have a significant impact on the
results of our study.
PAC-SYM and PAC-QoL questionnaires showed
higher scores in IBS-C group than in FC and NRC:
PAC-SYM abdominal symptom subscale, PAC-QoL
mean total score, physical discomfort, psychosocial
discomfort and worries and concerns subscales were
found to be higher in IBS-C. This reflects the close
association between the first four items of PAC-SYM
(abdominal discomfort, abdominal pain, bloating,
stomach cramps) and the typical symptoms of IBS.
These symptoms are likely responsible for the lower
QoL in IBS-C. Thus, the increase in perception of
constipation severity increases impairment of the
QoL, also increasing request of diagnostic tests and
therapies.
Different clinical characteristics, such as type of
constipation and comorbidities, may influence the
clinical approach of the gastroenterologists; thus, our
primary endpoint was to assess the diagnostic tools
and treatment suggested by Italian gastroenterologists
to their constipated patients, and the impact on the
clinical subgroups.
A surprising result, deserving discussion, is that
DRE was not performed in more than 40% of the pa-
tients, independently from being at first visit or at
Table 7 Suggested therapies requested by the gastroenterologist after their visit
THERAPIES 878 pts.(%) IBS-C (%) FC (%) NRC (%) p-value1
Life style recommendations 722 (82.2) 84.7 81.8 74.1 ns
Dietary suggestions 749 (85.3) 85.5 85.8 79.6 ns
Fibre supplements 489 (55.7) 60.7 53.2 55.6 ns
Herbal remedies 46 (5.2) 6.2 4.9 3.7 ns
Probiotics 318 (36.2) 40.4 33.5 42.6 ns
Lactulose/lactitole 58 (6.6) 4.7 7.8 3.7 ns
Macrogol 609 (69.4) 71.6 70.9 42.6 # <0.0001
Saline laxatives 31 (3.5) 4.0 3.5 1.9 ns
Stimulant laxatives 55 (6.3) 6.2 6.7 1.9 ns
Softening laxatives 46 (5.2) 5.1 5.7 1.9 ns
Prucalopride 126 (14.4) 13.1 15.7 7.4 ns
Suppositories/micro-enemas 198 (22.6) 23.6 21.3 29.6 ns
Enemas 238 (27.1) 29.5 26.6 20.4 ns
Antispasmodics 146 (16.6) 27.6 * ** 11.7 11.1 <0.0001
Anti-bloating agents 191 (21.8) 29.1 ^ 18.6 16.7 <0.005
Intestinal antibiotics 55 (6.3) 7.3 5.5 9.3 ns
Anxiolytics 108 (12.3) 14.6 11.5 9.3 ns
Antidepressants 60 (6.8) 8.0 6.0 9.3 ns
Psychotherapy 35 (4.0) 6.9 § 2.7 1.9 <0.05
Pelvic floor rehabilitation 169 (19.3) 14.6 22.2 ° 13.0 <0.05
Sacral neurostimulation 3 (0.3) // 0.4 1.9 ns
Anorectal surgery 20 (2.3) 1.5 2.7 1.9 ns
Colectomy 1 (0.1) // // 1.9 ns
Other 18 (2.1) 2.2 2.2 // ns
IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria
1p values are referred to the differences between IBS-C, FC and NRC groups, in particular
# p < 0.0001 vs IBS-C and NRC; * p < 0.0001 vs FC; ** p < 0.05 vs NRC; ^ p < 0.005 vs FC; § p < 0.05 vs FC; ° p < 0.05 vs IBS-C; ns: not statistically significant
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follow-up. DRE is the simplest and the most immedi-
ate method to assess anal tone and to collect infor-
mation about the pelvic floor conditions and to
detect early forms of rectal cancer or benign diseases
[19–22]. These data should be carefully taken into ac-
count when carrying out educational campaigns on
the diagnosis and treatment of CC.
The presence of comorbidities was likely the main reason
for the more frequent requested consultations (psychiatric/
psychological, urological, gynecological) underlining the
need for a stronger collaboration among different special-
ists for the correct management of CC, possibly creating
multidisciplinary teams.
Regarding the attitude towards diagnostic tests, we
want to stress that in about four out of five patients
gastroenterologists were not so confident on Rome III
criteria, and prescribed at least one diagnostic test,
more often in patients at first evaluation, mainly
blood tests, but also colonoscopy (requested more fre-
quently in patients older than 50 years), anorectal
manometry and measurement of colonic transit time.
As already shown in previous studies in a general
practitioner setting, abdominal ultrasound, although
not recommended by current guidelines, was quite
frequently requested, especially when abdominal pain
is present [23–26].
To exclude conditions potentially mimicking IBS, la-
boratory and breath tests were more frequently requested
in these patients, whereas in FC, defecography and ano-
rectal manometry were more frequently requested to
evaluate the presence of dyssynergic defecation. In NRC
patients fewer diagnostic tests were overall required, prob-
ably due to less severe symptoms and lesser impairment
of the QoL.
Overall, dietetic and lifestyle suggestions were the
most frequently suggested therapeutic options (>90%
of the patients) (Table 7). However, in the present
study, the gastroenterologists were often not confident
that these could be sufficient to solve the problem
and used macrogol as the first line laxative, both in
association with dietetic and lifestyle suggestion and
fibers.
Macrogol is effective and safe, and new liquid for-
mulations make it easier to dose; because taste is an
important factor for patients’ adherence, particularly
for long-time treatment, the formulations without
aroma made it more acceptable to patients [27]. On
the other hand further increasing fibers intake could
induce bloating and abdominal discomfort without
improving colonic transit time [28]. To control the
different symptoms of IBS (mainly abdominal pain
and bloating) gastroenterologists also used antispas-
modic drugs, psychotherapy and anti-bloating agents,
whereas pelvic floor rehabilitation was suggested more
often in FC patients, in whom functional defecation
disorders should be more frequent.
Surgery procedures (and sacral neurostimulation) were
infrequently suggested by gastroenterologists.
The gastroenterologists involved in this study rarely
prescribed laxatives such as lactulose/lactitole, and
stimulant, emollient or saline laxatives which still repre-
sent the most used laxatives in Italy. These drugs, which
cover about 40% of the Italian market [29], are more
often prescribed by general practitioners [23] and other
specialists than gastroenterologists.
Prucalopride, recently available on the Italian
market, was prescribed in about 13% of patients al-
though it was considered, probably because expen-
sive, a second/third line treatment, and prescribed
more frequently at a follow-up. At the time of the
study, linaclotide was not yet available on the Italian
market.
As previously reported for diagnostic tools, the
amount of therapy prescribed also increased by in-
creasing PAC-SYM and PAC-QoL scores; in NRC
patients, who displayed lighter symptoms, fewer
therapies were suggested. In conclusion, in our
country a gastroenterological evaluation of CC is
often delayed in patients with long lasting symptoms,
colonoscopy and blood tests are considered a “first
line” diagnostic tool, and DRE is insufficiently per-
formed. Furthermore, constipation is associated with
several comorbidities in most patients. Among Italian
gastroenterologists macrogol is the most frequently
used laxative, while in IBS-C patients a larger amount
of drugs is prescribed than in FC and NRC patients.
The study also provides several educational ideas to
improve the diagnostic and therapeutic approach to CC:
general practitioners and other specialists should be sug-
gested to address earlier such patients to a gastroenter-
ologist before long-term complications occur. DRE
should be performed in all patients, while echography
usefulness should be resized.
Conclusions
Chronic constipation is a common disorder that has a
remarkable impact on the quality of life. We report
on diagnostic and therapeutical experiences of Italian
gastroenterologists.
Patients with irritable bowel syndrome with constipa-
tion reported more severe symptoms and worsened
quality of life than functional constipation. Colonoscopy
and blood tests were the most prescribed tests and
Macrogol was the most prescribed laxative.
This study can provide several educational ideas to im-
prove the diagnostic and therapeutic approach to
Chronic Constipation.
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